Levofloxacin Hydrochloride Capsules

This product has a broad-spectrum antibacterial effect and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, and Gram-negative bacteria such as Haemophilus influenzae, Legionella pneumophila, and Neisseria gonorrhoeae. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Mycoplasma pneumoniae and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci. This product is the levorotatory form of ofloxacin, and its in vitro antibacterial activity is about twice that of ofloxacin. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death.

The main ingredient of this product is levofloxacin hydrochloride. Chemical name: (S)-(-)-9-fluoro-2.3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-fluoro-7H pyridine benzene Molecular weight: C18H20FN3O4

This product is a white film-coated tablet, which appears off-white or light yellow after removing the film.

Applicable to infections caused by sensitive bacteria: 1. Urinary and reproductive system infections, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute bronchial infections and lung infections caused by sensitive Gram-negative bacilli. 3. Gastrointestinal infections caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis.

Oral administration: 0.1-0.2g per time for adults, twice a day. For patients with severe conditions, it can be increased to three times a day.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache and other neurological symptoms, as well as rash, itching and other symptoms may occur. Transient liver function abnormalities may also occur, such as increased serum transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1% and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, abnormal taste, etc., which are generally tolerated and disappear quickly after the end of the treatment.

It is contraindicated for patients who are allergic to quinolones, pregnant or lactating women, infants and children.

Precautions for children: Patients under 18 years of age are prohibited. Precautions for pregnancy and lactation: 1. Women who are pregnant or may become pregnant are prohibited; 2. Women who are lactating are prohibited. Precautions for the elderly: Elderly patients often have impaired renal function. Since this product is partially excreted through the kidneys, it needs to be used in reduced doses.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When quinolone antibiotics are used in combination with theophylline, competitive inhibition with the cytochrome P450 binding site may lead to a significant reduction in the hepatic elimination of theophylline, prolonged blood elimination half-life (t1/2β), increased blood drug concentration, and symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, agitation, convulsions, palpitations, etc. Although this product has little effect on the metabolism of theophylline, theophylline blood concentration should still be measured and the dosage adjusted when used in combination. 3. When this product is used in combination with cyclosporine, the blood concentration of cyclosporine can be increased. The blood concentration of cyclosporine must be monitored and the dosage adjusted. 4. When this product is used in combination with the anticoagulant warfarin, the anticoagulant effect of the latter is slightly enhanced, but the patient should also be closely monitored when used in combination.

Keep away from light and store in sealed container.

0.1g (calculated as levofloxacin)

24 months

Hefei Shuboshi Pharmaceutical Co., Ltd.

• Founded in:

  2003-07-08

• Address:

  No. 35, Tianzhi Road, High-tech Zone, Hefei City, Anhui Province

• Tax NO.:

  9134010075099629XX

• Registered Funds:

  18.2 million yuan

• Email:

  Log in to view